Extracellular vesicles compartment in liquid biopsies: Clinical application

García-Romero, Noemí; Esteban-Rubio, Susana; Rackov, Gorjana; Carrión-Navarro, Josefa; Belda-Iniesta, Cristóbal; Ayuso-Sacido, Ángel

doi:10.1016/j.mam.2017.11.009

Cited by 66 publications

(51 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that there were some similarities between the distribution and chromosomal changes of Human blood is rich in biological information, and liquid biopsy can capture cancerous information at an early stage and prevent tumor progression as early as possible. Common liquid biopsy indicators are cfDNA, RNA, miRNA [13], and proteins (free proteins or proteins contained in CTCs, exosomes [14] or platelets [15]. cfDNA is commonly used to detect gene mutations, and is suitable for drug resistance and efficacy evaluation, but the blood contains a high abundance of non-tumor-derived cfDNA [16]; RNA is low in blood and not stable; Protein-based markers generally respond to disease progression stages depending on the level of content, but provide limited information that does not reflect changes in gene levels and tumor heterogeneity.…”

Section: Discussionmentioning

confidence: 99%

Aneuploid circulating tumor endothelial cells (CTECs) affect the detection of CTC, but they are fundamentally different

Lei¹,

Zhang²,

Liu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Aneuploidy is an important criterion for tumor cell identification. Like CTCs (circulating tumor cells), many CTECs (circulating tumor endothelial cells) have chromosomal aneuploidy. Affected by tumor microenvironment and detection method, the only identification index CD31 may not be comprehensive enough, which greatly affects the accuracy of CTCs detection. Methods Here, we explored the number distribution, expression of surface tumor markers and chromosome ploidy differences of aneuploid CTECs and CTCs in a total of 98 peripheral blood from normal volunteers, benign nodules and lung cancer patients, trying to find the differences between the two and the clinical significance of CTEC. Results We found that CTCs were mainly dominated by triploid and hyperploid (pentaploid or above), The former was mainly small CTCs, and the latter was mainly large CTCs. While the aneuploid CTECs were mostly large tetraploid cells. Combined detection of total CTC and CTEC numbers helped identify benign and malignant nodules. Furthermore, tetraploid CTC and CTEC had more obvious advantages than other ploids in identifying benign and malignant nodules. Conclusions Our findings indicated that the traditional method of distinguishing tumor and non-tumor cells by aneuploidy was not accurate. The presence of aneuploidy CTECs greatly interfered with the detection of CTCs, but they were different form CTC in cell size, chromosome ploidy distribution and had certain clinical significance. Combining CTC and CTEC had better diagnostic advantages

show abstract

Section: Discussionmentioning

confidence: 99%

Aneuploid circulating tumor endothelial cells (CTECs) affect the detection of CTC, but they are fundamentally different

Lei¹,

Zhang²,

Liu³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…• circulating tumor cells, 13,14 • circulating extracellular nucleic acids, including cell-free DNA (cfDNA), mRNA, and microRNA (miRNA), 7,15 • extracellular vesicles (e.g., exosomes), 16,17 • nucleosomes, 18,19 • various glycoproteins and antigens (e.g., PSA, CEA, CA 125, CA19-9, βHCG, αFP, etc.). 3,4 Although all these components of liquid biopsies have advantages and limitations (for reviews, see refs.…”

Section: Introductionmentioning

confidence: 99%

Life and death of circulating cell-free DNA

Kustanovich

Schwartz

Peretz

et al. 2019

Cancer Biology & Therapy

402

386

View full text Add to dashboard Cite

Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of biomarkers for minimally invasive serial monitoring of treatment responses in cancer management. We will review the current understanding of the origin of circulating cell-free DNA and different forms of DNA release (including various types of cell death and active secretion processes) and clearance routes. The dynamics of extracellular DNA in blood during therapy and the role of circulating DNA in pathophysiological processes (tumor-associated inflammation, NETosis, and pre-metastatic niche development) provide insights into the mechanisms that contribute to tumor development and metastases formation. Better knowledge of circulating tumor-specific cell-free DNA could facilitate the development of new therapeutic and diagnostic options for cancer management. ARTICLE HISTORY

show abstract

“…The fact that EVs shield their molecular cargo from degradation, increasing its stability, makes EV-associated DNA a potentially favourable alternative to cell-free DNA [76]. Although EVs, exosomes in particular, are well recognized as an important novel component of the tumor circulome suitable for biomarker analysis, most of the efforts until now have been made in exploring their protein and RNA (mRNA and miRNA) content [77][78][79] and very few studies have been focused on the analysis of their DNA cargo. The first paper describing the feasibility of the analysis of exosomal DNA as liquid biopsy was published in 2014 [80].…”

Section: Exosomal Dna (Exodna)mentioning

confidence: 99%

Circulating tumor DNA – Current state of play and future perspectives

Rubis

Krishnan

Bebawy

2018

Pharmacological Research

View full text Add to dashboard Cite

Cancer management paradigms are shifting towards a personalized approach thanks to the advent of the -omics technologies. Liquid biopsies, consisting in the sampling of blood and other bodily fluids, are emerging as a valid alternative to circulating tumor biomarkers and tumor tissue biopsies for cancer diagnosis, routine monitoring and prognostication. The content of a liquid biopsy is referred to as the "tumor circulome". Among its components, circulating tumor DNA (ctDNA), including both cell-free and exosome-associated DNA, is the most widely characterized element. ctDNA analysis has a tremendous capability in the diagnostic arena. Its potential has been demonstrated at each level of disease staging and management and supported by a recent FDA approval for companion diagnostic, and the investments being made by pharmaceutical companies in this sector are numerous. The approaches available for ctDNA analysis allow both quantitative and qualitative studies and range from PCR and dPCR-mediated single/multiple gene mutational assessment to whole genome next generation sequencing and methylation mapping. Although the principal object of a liquid biopsy is blood, other body fluids such as urine and saliva show potential as complementary DNA sources for tumor analysis. In this review we provide a synopsis on the state of play of current ctDNA application. We discuss the clinical significance of ctDNA analysis and review the state of the art of technologies being currently developed to this aim. We also discuss the current issues limiting ctDNA application and highlight the promising approaches being developed to overcome these.

show abstract

Extracellular vesicles compartment in liquid biopsies: Clinical application

Cited by 66 publications

References 98 publications

Aneuploid circulating tumor endothelial cells (CTECs) affect the detection of CTC, but they are fundamentally different

Aneuploid circulating tumor endothelial cells (CTECs) affect the detection of CTC, but they are fundamentally different

Life and death of circulating cell-free DNA

Circulating tumor DNA – Current state of play and future perspectives

Contact Info

Product

Resources

About